je.st
news
Actelion Sees Uptravi Price Of $160,000-170,000/Patient
2016-01-05 21:20:32| Biotech - Topix.net
Swiss drug company Actelion expects an average annual per-patient price for its new pulmonary arterial hypertension medicine in the United States of $160,000 to $170,000, before rebates, Chief Operating Officer Otto Schwarz told analysts on Tuesday. The drug, Uptravi, won approval from the U.S. Food and Drug Administration last month and went on sale this week, giving doctors another option to treat the deadly disease that kills victims within a few years.
Tags: price
sees
price sees
sees price
Category:Biotechnology and Pharmaceuticals